Such evidence signifies a promising future for AD blood-based diagnostics, and with the increasing number of studies currently being performed, as well as the encouraging rate at which the field is advancing, we are hopeful that reliable prognostic tau biomarkers that are associated with disease status and progression will be identified and brought into routine clinical practice. Here, MAPT is linked to Alzheimer disease.